




# **Administrative and Procedural issues**

-

## **Information & reporting**

*Ad hoc* meeting with GMO industry representatives  
Parma, Italy - 9 November 2017

# OUTLINE




# I. Submission of dossiers - Overall quality

<b>Tool</b>	2013 EFSA Administrative Guidance on the submission of applications for authorisation of GM plants under Regulation (EC) No 1829/2003		
<b>Scope</b>	To guide applicants in preparing and submitting a structured and comprehensive dossier, i.e. made of requested data/information to be presented in the most appropriate format		
<b>Our concern</b>	Dossiers of lower quality		
<b>Consequences</b>	Applicant :	Lengthy completeness check and delayed start of RA	
	EFSA :	Time-consuming extensive check of dossiers not up to enter the RA phase (e.g. MS consultation)	


# I. Submission of dossiers - Overall quality

A few basics to be met ...



# I. Submission of dossiers - Administrative GD

- Administrative GD = living document currently under revision to account for recent guidance documents and explanatory notes



- Publication foreseen end 2017
- Further update in the light of upcoming notes to guidance
- Guidance document on the submission of renewal applications under preparation

# I. Submission of dossiers - Applicability of GDs



## Principles

GDs not applied retroactively

Transition period , if any

## Facts

Not applicable in case of clarifications on existing data/info

Applicable to requests for new data/info that need to be generated

## Conclusion

New dossiers should fully comply with

- ☐ Agro/pheno → 24 June 2017
- ☐ Literature search → 10 October 2017
- ☐ Allergenicity → 22 December 2017
- 22 June 2018 or 2019

For non-IgE-mediated adverse immune to food

For endogenous allergenicity depending if plant material needs to be generated

## II. Risk assessment - Clock mechanism




### Brief reminder of **principles**

- Questions are not reiterated\*
- Within 30 WG from receipt of clock-stop letter, applicants are asked (1) to confirm that deadline to submit data can be met, or (2) to propose a new deadline (subject to justifications)
- Clock restarts at (1) receipt of requested datasets (full or partial\*), or (2) if requested datasets will not be submitted \*
- Spontaneous data are considered during the RA without stopping the clock

FYI Same principle of stop-and-restart the clock is applied to generic mandates based on the timeline set by the EC

## II. Risk assessment - Incoming info...



### Recent experiences re-additional dataset

- Complete...but of low quality
- Incomplete (e.g. statement referring to initial dossier but no additional evidence provided)
- Not submitted at the time of the request (spontaneously later during RA)
- Not submitted at all



## II. Risk assessment - Incoming info...



### Possible implications for EFSA and applicants owing to data gap

- To be detrimental to public trust in the RA system
- To trigger further delay in RA process and progress (e.g. additional WG meetings needed, discussion at WGs/Panel meeting postponed)
- Increased likelihood of inconclusive opinion

**Our present suggestion**      Catalogue of services?

## II. Risk assessment - Clarifications' teleconferences

- **EFSA's Catalogue of support initiatives** during the life-cycle of applications for regulated products
- Since our last meeting
  - **16 tele-meetings** (14 during RA, 2 post-adoption) on GM products for (continued) placing on the market
  - Broad range of questions

## II. Risk assessment - Clarifications' teleconferences

**Common goal...**common understanding for streamlining the RA

**Constraints** owing to the scope of such meetings, i.e.

- To clarify the scientific rationale of individual questions raised during the risk assessment;
- To ensure understanding of the question to be answered by the applicant.

Thanks to provide your questions/**points of concern ahead of the meeting**

**Follow up** e-mail/letter

## II. Risk assessment - EuropaBio comments on RA process

### **Objective**

To streamline the RA of GMOs and to reduce the timeline

### **(Generic) Suggestions**

- Questions from JRC-EURL should not prevent WGs to start discussing data
- WGs should kick-off RA of data immediately after validity of dossiers
- Need a procedure for better coordination of contractors' reports

## II. Risk assessment - EuropaBio comments on RA process

### Objective

To streamline the RA of GMOs and to reduce the timeline

### (Specific) Suggestions

- Questions to applicants
  - Critical questions triggering generation of new studies should be sent within 3 month timeline after validity
  - Minor clarifications should be asked within a 4 month timeline and only when major issues were solved
  - Follow-up questions should be sent within 1-3 months after receipt of 'previous' add. Dataset
  - Favours clusters of questions, irrespective of areas of risk
  - Questions should include a clear rationale
- When a report has been assessed 'positively', it should not be re-assessed owing to new guidelines or experts turn-over.

A modern, multi-story building with a white facade and horizontal slats. A large, curved, metallic structure is attached to the side. The building is set against a clear blue sky. In the foreground, there is a low, white, modern structure with large glass windows. The EFSA logo is visible on the left side of the building.

**EFSA GMO Unit**

*[gmo@efsa.europa.eu](mailto:gmo@efsa.europa.eu)*

**Thank you for your attention!**